NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Forecast, Price & News $2.34 +0.19 (+8.84%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.10▼$2.3850-Day Range$1.43▼$2.3452-Week Range$1.18▼$4.08Volume131,379 shsAverage Volume63,155 shsMarket Capitalization$85.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Black Diamond Therapeutics (NASDAQ:BDTX) StockBlack Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BDTX Stock News HeadlinesMay 25, 2023 | finance.yahoo.comBlack Diamond Therapeutics Insider Ups Holding By 82% During YearMay 18, 2023 | finance.yahoo.comBlack Diamond Therapeutics Insider Ups Holding By 82% During Year \June 4, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 14, 2023 | americanbankingnews.comWedbush Weighs in on Black Diamond Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:BDTX)May 13, 2023 | americanbankingnews.comFY2027 EPS Estimates for Black Diamond Therapeutics, Inc. Increased by Analyst (NASDAQ:BDTX)May 11, 2023 | msn.comWedbush Reiterates Black Diamond Therapeutics (BDTX) Neutral RecommendationMay 9, 2023 | markets.businessinsider.comBerenberg Bank Remains a Buy on Black Diamond Therapeutics (BDTX)May 9, 2023 | finanznachrichten.deBlack Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateJune 4, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 9, 2023 | finance.yahoo.comBlack Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 18, 2023 | finance.yahoo.comBlack Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology DaysApril 17, 2023 | tmcnet.comBlack Diamond Therapeutics Presents Trial in Progress PosterApril 17, 2023 | finance.yahoo.comBlack Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual MeetingMarch 13, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: DarioHealth (DRIO), Fulcrum Therapeutics (FULC) and Black Diamond Therapeutics (BDTX)March 9, 2023 | benzinga.comBlack Diamond Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results.March 9, 2023 | msn.comBlack Diamond Therapeutics GAAP EPS of -$0.59 beats by $0.04March 9, 2023 | finance.yahoo.comBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateFebruary 27, 2023 | finance.yahoo.comBlack Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 10, 2023 | morningstar.comBlack Diamond Therapeutics Inc Ordinary SharesJanuary 19, 2023 | finance.yahoo.comprivate equity firms who own 40% along with institutions invested in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw increase in their holdings value last weekJanuary 5, 2023 | finance.yahoo.comBlack Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 19, 2022 | finance.yahoo.comBlack Diamond Therapeutics Announces Changes to Board of DirectorsDecember 12, 2022 | finance.yahoo.comBlack Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology CompanyDecember 9, 2022 | finance.yahoo.comDown 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)December 9, 2022 | finance.yahoo.comBlack Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) recent US$17m market cap decline means a loss of US$21k for insiders who bought this yearDecember 6, 2022 | seekingalpha.comBlack Diamond Therapeutics: Selling For Large Discount To CashNovember 8, 2022 | finance.yahoo.comBlack Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateSee More Headlines BDTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDTX Company Calendar Last Earnings3/09/2023Today6/04/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BDTX CUSIPN/A CIK1701541 WebN/A Phone617-252-0848FaxN/AEmployees86Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-91,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.30% Return on Assets-51.58% Debt Debt-to-Equity RatioN/A Current Ratio8.40 Quick Ratio8.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book0.87Miscellaneous Outstanding Shares36,510,000Free Float33,201,000Market Cap$85.43 million OptionableNot Optionable Beta1.85 Key ExecutivesDr. David M. Epstein Ph.D. (Age 63)Co-Founder, Pres, CEO & Director Comp: $854.73kDr. Fang Ni Pharm.D. (Age 35)CFO, Principal Financial Officer and Chief Bus. Officer Comp: $639.23kMr. Brent Hatzis-Schoch Esq. (Age 57)J.D., COO & Gen. Counsel Comp: $610.48kDr. Elizabeth Buck Ph.D. (Age 47)Co-Founder & Chief Scientific Officer Ms. Erika Jones (Age 37)VP of Fin., Corp. Controller & Principal Accounting Officer Ms. Elizabeth L. Montgomery (Age 50)Chief People Officer Dr. Christopher D. Roberts Ph.D. (Age 52)Advisor Mr. Tai-An Lin Ph.D.Sr. VP of Translational Science & Discovery BiologyDr. Sergey Yurasov M.D. (Age 53)Ph.D., Chief Medical Officer Ms. Melanie MorrisonSr. VP of Devel. OperationsMore ExecutivesKey CompetitorsMiNK TherapeuticsNASDAQ:INKTDyadic InternationalNASDAQ:DYAITradeUP AcquisitionNASDAQ:UPTDTCR2 TherapeuticsNASDAQ:TCRRCognition TherapeuticsNASDAQ:CGTXView All CompetitorsInsiders & InstitutionsEcoR1 Capital LLCBought 908,963 shares on 5/15/2023Ownership: 3.263%Two Sigma Advisers LPSold 36,600 shares on 5/15/2023Ownership: 0.482%Two Sigma Investments LPSold 35,910 shares on 5/15/2023Ownership: 0.295%Belvedere Trading LLCSold 17,900 shares on 5/15/2023Ownership: 0.000%Dimensional Fund Advisors LPSold 26,602 shares on 5/12/2023Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions BDTX Stock - Frequently Asked Questions How have BDTX shares performed in 2023? Black Diamond Therapeutics' stock was trading at $1.80 on January 1st, 2023. Since then, BDTX stock has increased by 30.0% and is now trading at $2.34. View the best growth stocks for 2023 here. When is Black Diamond Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our BDTX earnings forecast. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) issued its quarterly earnings data on Thursday, March, 9th. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.04. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA). When did Black Diamond Therapeutics IPO? (BDTX) raised $151 million in an IPO on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Black Diamond Therapeutics' stock symbol? Black Diamond Therapeutics trades on the NASDAQ under the ticker symbol "BDTX." Who are Black Diamond Therapeutics' major shareholders? Black Diamond Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include EcoR1 Capital LLC (3.26%), BlackRock Inc. (2.07%), Two Sigma Advisers LP (0.48%), Two Sigma Investments LP (0.30%), Dimensional Fund Advisors LP (0.07%) and Federated Hermes Inc. (0.04%). Insiders that own company stock include Bradley J Phd Bolzon, Brent Hatzis-Schoch, Christopher D Roberts, David M Epstein, Fang Ni, Growth N V Biotech, Robert Alexander Ingram, Thomas Leggett and Versant Venture Capital Vi, L. View institutional ownership trends. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Black Diamond Therapeutics' stock price today? One share of BDTX stock can currently be purchased for approximately $2.34. How much money does Black Diamond Therapeutics make? Black Diamond Therapeutics (NASDAQ:BDTX) has a market capitalization of $85.43 million. The company earns $-91,170,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. How can I contact Black Diamond Therapeutics? Black Diamond Therapeutics' mailing address is 139 MAIN STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-252-0848 or via email at investors@bdtherapeutics.com. This page (NASDAQ:BDTX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.